USD
$0.00
(0.00%
)At Close (As of Dec 12, 2025)
$26.34M
Market Cap
-
P/E Ratio
-1.18
EPS
$6.26
52 Week High
$0.64
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$3.6M |
| Selling General And Administrative | $2.8M |
| Research And Development | $726K |
| Operating Expenses | $3.6M |
| Investment Income Net | - |
| Net Interest Income | -$9.8K |
| Interest Income | $7K |
| Interest Expense | $17K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $30K |
| Income Before Tax | -$3.6M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$3.6M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$3.6M |
| Ebitda | -$3.6M |
| Net Income | -$3.6M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$3.2M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | - |
| Capital Expenditures | $4 |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | - |
| Cashflow From Financing | $0 |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$3.6M |
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$3.6M |
| Selling General And Administrative | $2.8M |
| Research And Development | $726K |
| Operating Expenses | $3.6M |
| Investment Income Net | - |
| Net Interest Income | -$9.8K |
| Interest Income | $7K |
| Interest Expense | $17K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $30K |
| Income Before Tax | -$3.6M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$3.6M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$3.6M |
| Ebitda | -$3.6M |
| Net Income | -$3.6M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Lixte Biotechnology Holdings, Inc. is a clinical-stage biotechnology firm headquartered in East Setauket, New York, dedicated to developing breakthrough therapies for serious diseases using its proprietary biomarker technology. The company is at the forefront of precision medicine with a diverse pipeline of innovative compounds targeting critical unmet needs in oncology and neurodegenerative disorders. By leveraging its unique capability to identify and modulate specific enzymes, Lixte is strategically positioned within the biotechnology sector, making it an attractive investment opportunity for institutional investors focused on advancing therapeutic innovations.